Buscar
Cerus Corp
CERSAñadir a la lista de seguimiento
3.160USD
+0.160+5.33%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
633.00MCap. mercado
PérdidaP/E TTM
Más Datos de Cerus Corp Compañía
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Información de Cerus Corp
Símbolo de cotizaciónCERS
Nombre de la empresaCerus Corp
Fecha de salida a bolsaJan 31, 1997
Director ejecutivoGreenman (William M)
Número de empleados281
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 31
Dirección1220 Concord Avenue
CiudadCONCORD
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94520
Teléfono19252886000
Sitio Webhttps://www.cerus.com/
Símbolo de cotizaciónCERS
Fecha de salida a bolsaJan 31, 1997
Director ejecutivoGreenman (William M)
Ejecutivos de Cerus Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Kevin Dennis Green, CPA
Mr. Kevin Dennis Green, CPA
Chief Financial Officer, Vice President - Finance
Chief Financial Officer, Vice President - Finance
473.21K
+6.39%
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Independent Director
Independent Director
201.68K
+19.61%
Ms. Ann Lucena
Ms. Ann Lucena
Independent Director
Independent Director
172.28K
+34.83%
Dr. Hua Shan, M.D., Ph.D.
Dr. Hua Shan, M.D., Ph.D.
Independent Director
Independent Director
132.39K
+45.32%
Mr. William M. (Obi) Greenman
Mr. William M. (Obi) Greenman
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Ms. Chrystal N. Jensen, J.D.
Ms. Chrystal N. Jensen, J.D.
Chief Legal Office, General Counsel and Secretary
Chief Legal Office, General Counsel and Secretary
--
--
Dr. Frank R. Witney, Ph.D.
Dr. Frank R. Witney, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Richard J. Benjamin, Ph.D.
Dr. Richard J. Benjamin, Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vivek K. Jayaraman
Mr. Vivek K. Jayaraman
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Timothy L. (Tim) Moore
Mr. Timothy L. (Tim) Moore
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Kevin Dennis Green, CPA
Mr. Kevin Dennis Green, CPA
Chief Financial Officer, Vice President - Finance
Chief Financial Officer, Vice President - Finance
473.21K
+6.39%
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Independent Director
Independent Director
201.68K
+19.61%
Ms. Ann Lucena
Ms. Ann Lucena
Independent Director
Independent Director
172.28K
+34.83%
Dr. Hua Shan, M.D., Ph.D.
Dr. Hua Shan, M.D., Ph.D.
Independent Director
Independent Director
132.39K
+45.32%
Mr. William M. (Obi) Greenman
Mr. William M. (Obi) Greenman
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Ms. Chrystal N. Jensen, J.D.
Ms. Chrystal N. Jensen, J.D.
Chief Legal Office, General Counsel and Secretary
Chief Legal Office, General Counsel and Secretary
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Cerus Corp?
Los cinco principales accionistas de Cerus Corp son: Mr. Kevin Dennis Green, CPA
¿Cuántas instituciones poseen acciones de Cerus Corp (CERS)?
A fecha de 2026Q1, 277 instituciones poseen acciones de Cerus Corp, con un valor de mercado combinado de aproximadamente 147.40M, lo que representa el 73.57% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 4480533.00.
¿Cuál es la mayor fuente de ganancias de Cerus Corp?
El 2026Q1, el segmento empresarial Product generó la ganancia más alta para Cerus Corp, ascendiendo a 206.13M y representando el 88.17% de la ganancia total.